Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 15, 2020 (7 years ago)

Polyoxyl Lauryl Ether

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Polyoxyl Lauryl Ether (Polidocanol) Injection, LAURETH-9 (POLIDOCANOL) 5% INJECTABLE, For IV Use, 30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-060-3

Affected NDC 71283-0060-03

Compare with the code on your package — it is the most precise check available.

Drug: Polidocanol

Recalling firm
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
NDC code
71283-060-3
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0960-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Polidocanol recalls

See all
Class III · Low risk

Varithena (polidocanol injectable foam)

Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10 mL Luer Solo syringes (luer slip connection).

Terminated Packaging defect Biocompatibles UK, Ltd. D-0113-2025
Class II · Moderate risk

Polidocanol 50mg/Ml

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Terminated Sterility / contamination Pharmacy Innovations D-0231-2023
Class II · Moderate risk

Polidocanol 5% Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1625-2015

Other recalls by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical

All 2020 recalls
Class II · Moderate risk

Cholecalciferol

Lack of Assurance of Sterility

Terminated Sterility / contamination Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0251-3 D-0993-2020
Class II · Moderate risk

Cholecalciferol

Lack of Assurance of Sterility

Terminated Sterility / contamination Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0210-3 D-0992-2020